

Organogenesis Holdings Inc

11:45 15 Mar 2019

Regenerative medicine company Organogenesis rallies after announcing \$100M credit facility

Organogenesis Holdings Inc (NASDAQ:ORGO) advanced Friday after announcing a \$100 million credit facility.

The credit deal with Silicon Valley Bank, the lead agent, and MidCap Financial consists of a \$60 million term loan facility and a \$40 million revolving credit facility.

Shares of the regenerative medicine company climbed 3.2% to \$9.82 in Friday's Nasdaq trading.

READ: True Leaf Medicine grows footprint with new brand identity, expands pet product line

The proceeds from the term loan and revolving credit facility will be used for general corporate purposes, the repayment of the company's credit facility and a lease with Eastward Capital Partners.

The agreement requires the achievement of certain financial milestones in order to draw the final \$20 million of the term loan facility.

"Silicon Valley Bank has been a great partner to Organogenesis, and we appreciate their continued support with this new credit agreement," Organogenesis Chief Financial Officer Tim Cunningham said in a statement. "This new term loan and revolving credit facility enhances our balance sheet and allows us to continue to execute our strategic growth objectives."

Based in Canton, Massachusetts, the company offers bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine.

-This story has been updated to give the latest stock price-

Contact Dennis Fitzgerald at dennis@proactiveinvestors.com

Price: US\$9.5

Market Cap: US\$924.37M

1 Year Share Price Graph



March 2018 September 2018 March 2019

Share Information

Code: ORGO

Listing: NASDAQ

52 week High Low
\$310.90 \$6.28

Sector: Health Care, Equipment & Services

Website: organogenesis.com

Company Synopsis:

Based in Canton, Massachusetts, Organogenesis Holdings Inc. is a regenerative medicine company offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics.

Author:

Proactive Investors Ltd

+44 (0)207 989 0813

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

Proactive Investors is a publisher and is not registered with or authorised by the Financial Conduct Authority (FCA). You understand and agree that no content published constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any

specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.